Analyst ratings often influence investor sentiment and can impact a company's stock price. In this case, Kura Oncology has received 8 bullish ratings and no bearish or indifferent ratings in the last quarter, which is a positive sign. Additionally, the average 12-month price target for the company has increased by 18.75%, indicating that analysts have a positive outlook for the company's future performance.